{"id":"placebo-to-match-deucravacitinib","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Muscle spasms"}]},"_chembl":null,"_fixedAt":"2026-03-30T12:44:52.323840","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TYK2 is a non-receptor tyrosine kinase involved in the signaling of various cytokines. By inhibiting TYK2, deucravacitinib reduces the activity of these cytokines, leading to anti-inflammatory effects.","oneSentence":"Deucravacitinib is a small molecule that acts as a selective tyrosine kinase 2 (TYK2) inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:49.617Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT06143878","phase":"PHASE3","title":"A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-01","conditions":"Plaque Psoriasis","enrollment":774},{"nctId":"NCT06220604","phase":"PHASE3","title":"A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-03-09","conditions":"Plaque Psoriasis","enrollment":731},{"nctId":"NCT06973291","phase":"PHASE3","title":"A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2025-07-09","conditions":"Plaque Psoriasis","enrollment":606},{"nctId":"NCT04772079","phase":"PHASE3","title":"A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-03-23","conditions":"Plaque Psoriasis","enrollment":153},{"nctId":"NCT06532136","phase":"PHASE2","title":"Deucravacitinib Rosacea","status":"WITHDRAWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2024-11","conditions":"Papulopustular Rosacea","enrollment":""},{"nctId":"NCT03956953","phase":"PHASE1","title":"Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-04-04","conditions":"Autoimmune Diseases","enrollment":135}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match deucravacitinib","genericName":"Placebo to match deucravacitinib","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Deucravacitinib is a small molecule that acts as a selective tyrosine kinase 2 (TYK2) inhibitor. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}